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country (5). These cases might be secondary to expo-
sure to the 9-banded armadillo (Dasypus novemcinctus), 
which lives in the area (2). Most HD patients in Louisi-
ana, Texas, and Florida who had not traveled outside the 
United States were infected with the M. leprae strain 3I-
2-v1, which is found in most infected armadillos (2). Al-
though direct contact with armadillo blood or flesh poses 
the highest risk, HD has been reported in persons with-
out direct exposure (8). These patients might have had 
exposure to contaminated soil (9). Alternatively, other 
environmental reservoirs might be responsible, exempli-
fied by the discovery of infected Eurasian red squirrels 
(Sciurus vulgaris) in the British Isles (10).
M. leprae genomic analysis strongly suggests that our 
patient acquired the infection with the armadillo-associated 
M. leprae strain during a trip to Florida. This case high-
lights the possibility of HD being acquired within North 
America without obvious exposure to known animal res-
ervoirs. Travelers to the southern United States should be 
advised to avoid contact with armadillos.
Acknowledgments
We thank the staff at National Hansen’s Disease Program,  
Baton Rouge, Louisiana, USA, for performing bacteriologic 
index analyses and genotyping.
About the Author
Dr. Bonnar, an infectious diseases graduate, completed a clinical 
fellowship in antimicrobial stewardship at the University of 
Toronto in Toronto, Ontario, Canada. His primary research 
interests include quality improvement projects to optimize 
antimicrobial use.
References
  1. Truman RW, Andrews PK, Robbins NY, Adams LB,  
Krahenbuhl JL, Gillis TP. Enumeration of Mycobacterium  
leprae using real-time PCR. PLoS Negl Trop Dis. 2008;2:e328. 
http://dx.doi.org/10.1371/journal.pntd.0000328
  2. Truman RW, Singh P, Sharma R, Busso P, Rougemont J,  
Paniz-Mondolfi A, et al. Probable zoonotic leprosy in the  
southern United States. N Engl J Med. 2011;364:1626–33.  
http://dx.doi.org/10.1056/NEJMoa1010536
  3. Sharma R, Singh P, Loughry WJ, Lockhart JM, Inman WB,  
Duthie MS, et al. Zoonotic leprosy in the southeastern United 
States. Emerg Infect Dis. 2015;21:2127–34. http://dx.doi.org/ 
10.3201/eid2112.150501
  4. Public Health Agency of Canada. Reported cases from 1924 to 
2014 in Canada—notifiable diseases on-line. 2016 June 28 [cited 
2016 Nov 21]. http://diseases.canada.ca/notifiable/charts?c=plt
  5. US Department of Health and Human Services Health Resources 
and Services Administration National Hansen’s Disease  
Program. Highlights from a summary of Hansen’s disease  
(leprosy) in the United States 2015. 2016 [cited 2016 Nov 21]. 
http://www.hrsa.gov/hansensdisease/dataandstatistics.html
  6.  Boggild AK, Correia JD, Keystone JS, Kain KC. Leprosy in  
Toronto: an analysis of 184 imported cases. CMAJ. 2004;170:55–9.
  7. Truman R, Fine PE. ‘Environmental’ sources of Mycobacterium 
leprae: issues and evidence. Lepr Rev. 2010;81:89–95.
  8. Marcos LA, Conerly S, Walker S. Leprosy. Am J Trop Med Hyg. 
2014;91:216. http://dx.doi.org/10.4269/ajtmh.13-0668
  9. Lavania M, Katoch K, Katoch VM, Gupta AK, Chauhan DS, 
Sharma R, et al. Detection of viable Mycobacterium leprae in soil 
samples: insights into possible sources of transmission of leprosy. 
Infect Genet Evol. 2008;8:627–31. http://dx.doi.org/10.1016/ 
j.meegid.2008.05.007
10. Avanzi C, Del-Pozo J, Benjak A, Stevenson K, Simpson VR,  
Busso P, et al. Red squirrels in the British Isles are infected with 
leprosy bacilli. Science. 2016;354:744–7. http://dx.doi.org/10.1126/
science.aah3783
Address for correspondence: Paul E. Bonnar, Dalhousie University, 
Infectious Diseases, 5072, 5th Fl Dickson Bldg, 5780 University Ave, 
Halifax, NS B3H 1V7, Canada; email: paule.bonnar@nshealth.ca
Emmonsia helica Infection  
in HIV-Infected Man,  
California, USA
Martin Rofael, Ilan S. Schwartz, Lynne Sigler,  
Li K. Kong, Nicholas Nelson
Author affiliations: Highland Hospital, Oakland, California, USA  
(M. Rofael, L.K. Kong, N. Nelson); University of Manitoba,  
Winnipeg, Manitoba, Canada (I.S. Schwartz); University of Texas 
Health San Antonio, San Antonio, Texas, USA (I.S. Schwartz); 
University of Alberta, Edmonton, Alberta, Canada (L. Sigler)
DOI: https://doi.org/10.3201/eid2401.170558
Emmonsia-like fungi have rarely been reported from North 
America. We report a fatal case of E. helica infection 
in a man with advanced HIV infection from California, 
USA, who had progressive respiratory failure and a 
brain abscess.
In January 2016, a 40-year-old man sought care at a hospital in Alameda County, California, USA, with a 
2-week history of progressive cough, dyspnea, pleuritic 
chest pain, and headache associated with fevers, chills, and 
night sweats. He had lost 45 kg during the past month. He 
had a history of inconsistently treated HIV infection and a 
10-pack-per-year smoking history. He had emigrated from 
Mexico 10 years earlier, lived in the East Bay, and had trav-
eled to the Central Valley of California.
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On examination, he was cachectic, afebrile, hypoxic, 
and tachypneic. He had oral thrush, bilateral lower lobe 
crackles, and decreased breath sounds. The rest of the ex-
amination, including neurologic and skin assessments, was 
unremarkable.
Chest radiograph and computerized tomographic scan 
showed diffuse micronodularities with cavitary lesions in 
both lungs (Figure, panels A, B). Magnetic resonance im-
aging of the brain revealed a 6-mm ring-enhancing cerebel-
lar lesion (Figure, panel C).
Laboratory results revealed a CD4 count and viral load 
of 5 cells/µL and 15,000 copies/mL, respectively. Blood 
leukocyte count was 14.9 × 109 cells/µL (reference 4.5–11 
× 109 cells/µL), and hemoglobin was 11 g/dL (reference 
13.5–17.5 g/dL). Lactate dehydrogenase, alkaline phos-
phatase, and γ-glutamyl transferase were 284 units/L (ref-
erence 125–243 U/L), 148 units/L (reference 38–126 U/L), 
and 242 units/L (reference 3–95 U/L), respectively. Cere-
brospinal fluid analyses, including cell count, protein, and 
glucose measurements, showed standard results.
Molecular testing of bronchoalveolar lavage (BAL) 
fluid for respiratory viruses showed negative results. Se-
rologic test results for blood and urine for coccidioido-
mycosis, cryptococcosis, toxoplasmosis, and tuberculosis 
were negative, but the Histoplasma galactomannan urine 
antigen test (MiraVista, Indianapolis, IN, USA) result was 
positive at >25 ng/mL (reference <0.5 ng/mL). Examina-
tion of cerebrospinal fluid with Gram, acid-fast, and India 
ink stains and aerobic, mycobacterial, and fungal cultures 
were negative for organisms. Cytopathologic examination 
of BAL fluid and lung biopsy samples showed nonnecrotiz-
ing granulomas with hematoxylin and eosin stain and both 
hyphal and yeast forms with fungal stains. The yeasts ex-
hibited multiple budding with broad bases (Figure, panel 
D). No organisms were seen with an acid-fast stain. Mul-
tiple sputum cultures were negative for mycobacteria.
Empiric treatment was initiated for coccidioidomyco-
sis, Pneumocystis jirovecii pneumonia, tuberculosis, and 
bacterial sepsis with intravenous fluconazole; trimethoprim– 
sulfamethoxazole with steroids; rifampin, isoniazid, pyra-
zinamide, and ethambutol; and broad-spectrum antimicro-
bial drugs. On hospital day 2, the patient had hypoxic re-
spiratory arrest and was intubated. Antifungal drugs were 
changed to micafungin on day 3 and then to liposomal am-
photericin B (5 mg/kg/day) on day 6, and he was extubated 
later that day. Tuberculosis therapy was discontinued on day 
15. Antiretroviral therapy was held because of concern that 
immune reconstitution might worsen the patient’s cerebellar 
lesion. A spontaneous pneumothorax and respiratory failure 
developed that required reintubation on day 31. His family 
chose comfort care, and antifungal therapy was stopped on 
day 41. He died on day 43; autopsy was declined.
We sent a mold grown from BAL to a mycology ref-
erence laboratory for identification. On microscopic exam-
ination of the mold phase, conidia were absent in all sub-
cultures. DNA sequences of the D1/D2 region of the large 
subunit and internal transcribed spacer region of the ribo-
somal RNA gene were compared with GenBank nBLAST 
database (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_
TYPE=BlastSearch); sequence similarities of 100% and 
99%, respectively, were demonstrated for Emmonsia helica 
strains (including UAMH 3398, UAMH 10539, and UAMH 
10593; UAMH Centre for Global Microfungal Biodiversity, 
University of Toronto, Toronto, Ontario, Canada).
We conducted antifungal susceptibility testing of the 
mold phase. MICs (µg/mL) to fluconazole, itraconazole, 
posaconazole, voriconazole, and amphotericin B were 8, 
0.125, 0.125, <0.03, and 0.06, respectively.
Emmonsia-like fungi are an emerging group of patho-
gens reported globally, which predominantly cause dis-
seminated disease of immunocompromised persons (1). 
One of these, E. helica, was originally recorded from 
North America (2). The first reported case occurred in 
Alberta, Canada, in 1970 in a farmer with a fatal pneu-
monia and encephalitis syndrome (3). A fungal patho-
gen isolated postmortem from brain and lung tissue 
was initially identified as Blastomyces dermatitidis on 
the basis of serologic and histopathologic findings, but 
Figure. Emmonsia helica infection in an immunocompromised man, California, USA, 2016. A) Chest radiograph with diffuse 
micronodularities throughout both lung fields. B) Computed tomographic scan with diffuse micronodular pulmonary disease. C) Axial 
magnetic resonance image with 6-mm ring-enhancing lesion in the right cerebellum adjacent to the fourth ventricle. D) Grocott’s 
methenamine-silver stain showing broad-based budding yeast. Original magnification ×400. 
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its features in culture were atypical (3). In 2015, Sigler 
determined that this isolate belonged to a new Emmon-
sia-like species, which she described as E. helica (3). 
Another fatal case of Emmonsia infection was reported 
from California in a patient after an orthotopic liver 
transplant (4). An isolate from that patient also was con-
firmed as E. helica (I. Schwartz et al., unpub. data).
Although the travel history for the second case-patient 
was not reported (4) and the patient in this report had re-
sided in Mexico, these cases suggest that the area of en-
demicity of E. helica may include California. This finding 
is further supported by 2 other fatal cases of atypical my-
coses reported in HIV-infected men from California (5); 
histopathologic findings of hyphae and multiple budding 
yeasts were consistent with E. helica (I. Schwartz et al., 
unpub. data). Investigations are under way to characterize 
the geographic and host range of E. helica and to clarify 
the phylogenetic relationships among members of the fam-
ily Ajellomycetaceae comprising the genera Emmonsia, 
Blastomyces, Histoplasma and others because recent stud-
ies have uncovered far greater complexity than previously 
supposed (1,6).
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During January–April 2015, a major outbreak of conjunctivi-
tis on Réunion Island caused a large public health impact. 
On the basis of general practitioner consultations, emergen-
cy department visits, and eye medication sales during the 
13-week epidemic, we estimated a total healthcare cost of 
€3,341,191 from the outbreak.
During January–April 2015, a major outbreak of acute hemorrhagic conjunctivitis occurred on Réunion Is-
land, causing a heavy impact on the national healthcare 
system of France (1). Réunion Island, a French overseas 
administrated territory, is located in the Indian Ocean be-
tween Madagascar and Mauritius; it has a surface area of 
2,512 km2 and a population of ≈840,000 (1.3% of France’s 
population, including the nation’s overseas territories; 
https://www.insee.fr/fr/statistiques/2119468). 
The island is included in the national health insurance 
(NHI) program of France. Réunion Island’s health system 
is similar to that of France; however, most patients on the 
island do not pay provider health fees directly. NHI pays 
the general practitioner (GP), the pharmacist, or hospi-
tal. Rarely, the patients pay for the GP consultations and 
emergency department (ED) visits, but these costs will be 
refunded to the patients by the NHI. Healthcare costs are 
higher (≈30%) on the island than in mainland France. In 
2015, total healthcare expenditures in Réunion Island were 
